Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity

European Journal of Immunology

Volumn 37, Issue 3, 2007, Pages 758-767

  Simon, Anna Katharina ^b   Jones, Emma ^b   Richards, Hannah ^a   Wright, Kate ^a   Betts, Gareth ^a   Godkin, Andrew ^a   Screaton, Gavin ^c   Gallimore, Awen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Fas ligand; Innate tumour immunity; Regulatory T cells

Indexed keywords

CANCER VACCINE; FAS LIGAND; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR REJECTION; VACCINATION; ACTIVE IMMUNIZATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; FAS LIGAND PROTEIN; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147129582     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636593     Document Type: Article

References (29)

1. T cells. Immunology 2002. 107: 5-9.
2. + regulatory T cells and their ligands: Implications for immunotherapy. Immunity 2004. 20: 107-118.
3. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942-949.
4. + regulatory T cells. Semin. Immunol. 2004. 16: 89-98.
5. Barnett, B., Kryczek, I., Cheng, P., Zou, W. and Curiel, T. J., Regulatory T cells in ovarian cancer: Biology and therapeutic potential. Am. J. Reprod. Immunol. 2005. 54: 369-377
6. Simon, A. K., Gallimore, A., Jones, E., Sawitzki, B., Cerundolo, V. and Screaton, G. R., Fas ligand breaks tolerance to self-antigeris and induces tumor immunity mediated by antibodies, Cancer Cell 2002. 2: 315-322.
7. Seino, K., Kayagaki, N., Okumura, K. and Yagita, H., Antitumor effect of locally produced CD95 ligand. Nat. Med. 1997 3: 165-170.
8. Hohlbaum, A. M., Moe, S. and Marshak-Rothstein, A., Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J. Exp. Med. 2000. 191: 1209-1220.
9. Shimizu, M., Yoshimoto, T., Sato, M., Morimoto, J., Matsuzawa, A. and Takeda, Y., Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/ Apo-1 (CD95) ligand-expressing tumor. Int. J. Cancer 2005. 114: 926-935.
10. Shimizu, M., Fontana, A., Takeda, Y., Yoshimoto, T., Tsubura, A. and Matsuzawa, A., Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity. Cell. Immunol. 2001. 207: 41-48.
11. Seino, K., Kayagaki, N., Okumura, K. and Yagita, H., Antitumor effect of locally produced CD95 ligand. Nat. Med. 1997 3: 165-170.
12. Chen, J. J., Sun, Y. and Nabel, G. J., Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 1998. 282: 1714-1717.
13. Hohlbaum, A. M., Gregory, M. S., Ju, S. T. and Marshak-Rothstein, A., Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 2001. 167: 6217-6224.
14. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005. 202: 1075-1085.
15. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 2006. 176: 1582-1587.
16. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002. 2: 1.
17. Miwa, K., Asano, M., Horai, R., Iwakura, Y., Nagata, S. and Suda, T., Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 1998. 4: 1287-1292.
18. Igney, F. H., Behrens, C. K. and Krammer, P. H., CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int. J. Cancer 2005. 113: 78-87.
19. Taams, L. S., Smith, J., Rustin, M. H., Salmon, M., Poulter, L. W. and Akbar, A. N., Human anergic/suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Eur. J. Immunol. 2001. 31: 1122-1131.
20. + regulatory T cells are highly susceptible to CD95 ligand-but not to TCR-mediated cell death. J. Immunol. 2005. 175: 32-36.
21. - regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004. 34: 336-344.
22. Dasch, J. R., Pace, D. R., Waegell, W., Inenaga, D. and Ellingsworth, L., Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J. Immunol. 1989. 142: 1536-1541.
23. Salazar-Mather, T. P., Lewis, C. A. and Biron, C. A., Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1alpha delivery to the liver. J. Clin. Invest. 2002. 110: 321-330.
24. Yokoyama, W. M., Kim, S. and French, A. R., The dynamic life of natural killer cells. Annu. Rev. Immunol. 2004. 22: 405-429.
25. Blattman, J. N. and Greenberg, P. D., Cancer immunotherapy: A treatment for the masses. Science 2004. 305: 200-205.
26. Martin-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A. and Sallusto, F., Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 2004. 5: 1260-1265.
27. Rescigno, M., Piguet, V., Valzasina, B., Lens, S., Zubler, R., French, L., Kindler, V. et al., Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: A new role for Fas ligand in inflammatory responses. J. Exp. Med. 2000. 192: 1661-1668.
28. Lowenthal, J. W., Corthesy, P., Tougne, C., Lees, R., MacDonald, H. R. and Nabholz, M., High and low affinity IL 2 receptors: Analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J. Immunol. 1985, 135: 3988-3994.
29. Koo, G. C. and Peppard, J. R., Establishment of monoclonal anti-Nk-1.1 antibody. Hybridoma 1984. 3: 301-303.